查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球臨床試驗影像市場：按軟體/服務、模式、治療領域和最終用戶分類 - 預測（~2029 年）
市場調查報告書
商品編碼
1565796

全球臨床試驗影像市場：按軟體/服務、模式、治療領域和最終用戶分類 - 預測（~2029 年）

Clinical Trial Imaging Market by Software & Service (Operational Imaging, Trial Design), Modality (CT, MRI, X-Ray, PET, Ultrasound), Therapeutic Area (Infectious, Oncology, CNS, CVD), End User (Pharma, Biotech, CROs) - Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 249 Pages | 訂單完成後即時交付

價格

全球臨床試驗影像市場規模預計將從2024年的14.2億美元增加到2029年的20.7億美元，複合年成長率為7.8%。

市場成長促進因素包括生物技術和製藥行業的擴張、研發費用的增加以及 CRO（委外研發機構）的數量。另一方面，預測期內限制市場成長的主要因素是臨床試驗的高成本和影像系統的高實施成本。

調查範圍
調查年份 2022-2029
基準年 2023年
預測期 2024-2029
單元 10億美元
部分 按服務/軟體、按方式、按治療領域、按最終用戶、按地區
目標區域 北美、歐洲、亞太地區、拉丁美洲、中東/非洲、海灣合作理事會

“從服務和軟體來看，服務領域在預測期內顯示出市場上最快的成長率。”

2023年臨床試驗影像市場中，服務領域呈現最快的成長速度。不斷增加的研發費用、不斷增加的臨床試驗數量以及對新疾病治療和診斷的需求是促進該細分市場成長的主要因素。

“醫療設備製造商領域的複合年成長率最高。”

2023年成長率最高的細分市場是醫療設備製造商。這是因為醫療設備製造商細分市場的主要成長要素是醫療設備製造商研發費用和研發活動的增加以及醫療設備市場的成長。

“亞太地區：成長最快的區域臨床試驗影像市場”

預計亞太地區在預測期內的複合年成長率最高。大量中小型企業、大量未經治療的臨床試驗人群、臨床研究中動物使用的法規不那麼嚴格，以及對法規和語言有深刻理解的本地 CRO 的存在；研究人員、臨床試驗成本低等是研發部門的主要驅動力。這些促進因素是由於研發成本增加以及將藥物研究外包給亞洲開發中國家的趨勢不斷成長。

本報告研究和分析了全球臨床試驗影像市場，提供了關鍵促進因素和限制因素、競爭格局和未來趨勢的資訊。

目錄

第1章簡介

第2章調查方法

第3章執行摘要

第 4 章重要考察

  • 臨床試驗影像市場概述
  • 按服務/軟體分類的臨床試驗影像市場佔有率(2024/2029)
  • 按模式分類的臨床試驗影像市場佔有率（2024 年和 2029 年）
  • 按治療領域分類的臨床試驗影像市場佔有率（2024 年和 2029 年）
  • 最終用戶臨床試驗影像市場佔有率（2024 年和 2029 年）
  • 臨床試驗影像市場：區域成長機會

第5章市場概況

  • 介紹
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會
    • 任務
  • 價格分析
  • 專利分析
  • 貿易分析
    • X光設備貿易分析（HS編碼9022）
    • CT設備貿易分析（HS編碼902212）
  • 價值鏈分析
  • 供應鏈分析
  • 生態系分析
  • 波特五力分析
  • 主要相關利益者和採購標準
  • 監管分析
  • 主要會議和活動（2023-2024）
  • 技術分析
    • 主要技術
    • 互補技術
  • 影響客戶業務的趨勢/干擾
  • 案例研究分析
  • 人工智慧/產生人工智慧對臨床試驗影像市場的影響

第6章臨床試驗影像市場：依服務/軟體分類

  • 介紹
  • 服務
    • 營運影像服務
    • 先導化合物分析服務
    • 系統及技術支援服務
    • 測試設計和諮詢服務
  • 軟體

第7章臨床試驗影像市場：按模式

  • 介紹
  • CT
  • MRI
  • 超音波
  • PET
  • X光
  • 其他方式

第8章臨床試驗影像市場：依治療領域

  • 介紹
  • 瘤
  • 感染疾病
  • 神經
  • 心血管疾病
  • 內分泌
  • 免疫疾病
  • 其他治療領域

第9章臨床試驗影像市場：依最終使用者分類

  • 介紹
  • 製藥和生物技術公司
  • 醫療設備製造商
  • CRO
  • 學術機構、政府研究機構
  • 其他最終用戶

第10章臨床試驗影像市場：按地區

  • 介紹
  • 北美洲
    • 北美宏觀經濟展望
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲宏觀經濟展望
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 亞太宏觀經濟展望
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 拉丁美洲
    • 拉丁美洲宏觀經濟展望
    • 巴西
    • 墨西哥
    • 其他拉丁美洲
  • 中東/非洲
  • 海灣合作理事會國家

第11章競爭格局

  • 介紹
  • 主要企業策略/主要企業
  • 收益分析（2021-2023）
  • 市場佔有率分析（2023）
  • 企業評價矩陣：主要企業（2023年）
  • 企業評估矩陣：Start-Ups/中小企業（2023）
  • 公司評價及財務指標
  • 競爭場景

第12章 公司簡介

  • 主要企業
    • ICON PLC
    • MEDPACE
    • CLARIO
    • IXICO PLC
    • RESONANCE HEALTH LTD.
    • RADIANT SAGE
    • WCG CLINICAL
    • CARDIOVASCULAR IMAGING TECHNOLOGIES
  • 其他公司
    • MEDICAL METRICS, INC.
    • PRISM CLINICAL IMAGING
    • BOSTON IMAGING CORE LAB
    • VOIANT
    • CALYX
    • BIOSPECTIVE INC.
    • PROSCAN IMAGING
    • MICRON, INC.
    • IMAGING ENDPOINTS
    • PERSPECTUM
    • PHARMTRACE
    • NAVITAS LIFE SCIENCES
    • MEDIAN TECHNOLOGIES
    • INVICRO, LLC
    • IMAGE CORE LAB
    • IMAGE ANALYSIS GROUP (IAG)

第13章附錄

Product Code: MD 4818

According to projections, the global clinical trial imaging market is expected to grow at a compound annual growth rate (CAGR) of 7.8%, from USD 1.42 billion in 2024 to USD 2.07 billion by 2029. Factors driving the market's growth include the biotechnology and pharmaceutical industries' expansion, the rise in R&D spending, and the number of Contract Research Organizations (CROs). However, the primary factors impeding the market's growth during the projection period are the high cost of clinical trials and the high implementation cost of imaging systems.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD Billion)
SegmentsBy Service & software, modality, therapeutic area, end user and region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, the Middle East & Africa and GCC

"By service & software, the service sector had the fastest growth rate in the clinical trial imaging market throughout the projected period."

Based on type, services and software comprise the clinical trial imaging industry. In the clinical trial imaging market in 2023, the service sector had the fastest growth rate. The operational imaging services, reader analysis services, system & technical support services, and trial design consulting services are further subdivided under the services sector based on type. Growing R&D expenditures, an increase in clinical trials, and the need for novel illness treatments and diagnostics are the main factors contributing to this segment's growth.

"Medical device manufacturers segment accounted for the highest CAGR."

The pharmaceutical and biotechnology firms, medical device manufacturers, contract research organizations, academic and government research institutes, and other end users are the segments of the clinical trial imaging market based on end user. The segment with the highest growth rate in 2023 was medical device manufacturers. This can be explained by the fact that the major growth drivers of the medical device manufacturers segment are the rising R&D expenditures and R&D activity by medical device manufacturers as well as the growing medical device market.

"Asia Pacific: The fastest-growing region clinical trial imaging market."

The markets for clinical trial imaging across North America, Europe, Asia Pacific, Latin America, the Middle East and Africa and GCC countries comprise the global market. Over the course of the projection period, the Asia Pacific area is expected to record the greatest CAGR. The large number of SMEs, the presence of a large treatment-naive population for clinical trials, less-stringent regulations governing the use of animals in clinical research, the availability of local CROs with strong regulatory and linguistic understanding, the presence of highly qualified researchers, and the low cost of clinical trials are the major factors driving the R&D sector. These drivers driving the market's expansion are therefore due to the rise in R&D expenditures and the increasing trend of outsourcing pharmaceutical research to developing Asian countries.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
  • By Designation: C-level - 27%, D-level - 18%, and Others - 55%
  • By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and the Middle East & Africa - 4%

Prominent companies are ICON plc. (Ireland), BioTelemetry Inc. (US), Biomedical Systems Corporation (US), Medpace Holdings, Inc. (US), IXICO plc. (UK), Resonance Health Ltd. (Australia), Radiant Sage LLC. (US), BioClinica Inc. (US), Intrinsic Imaging LLC. (US), Cardiovascular Imaging Technologies LLC. (US), Medical Metrics Inc. (US), Prism Clinical Imaging, Inc. (US), Boston Imaging Core Lab LLC. (US), anagram 4 clinical trials (Spain), Lyscaut Medical Imaging Company (Belgium), Calyx Group (UK), Bioseptive Inc. (Canada), ProScan Imaging LLC. (US), Micron Inc. (Japan), Imaging Endpoints LI, LLC (US), Perspectum Ltd. (UK), Pharmtrace klinische Entwicklung GmbH (Germany), WorldCare Clinical, LLC (US), Median Technologies (France) and Invicro. LLC. (US).

Research Coverage:

This research report categorizes the clinical trial imaging market by service & software, modality, therapeutic area, end user and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the clinical trial imaging market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the clinical trial imaging market. Competitive analysis of upcoming startups in the clinical trial imaging market ecosystem is covered in this report.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall clinical trial imaging market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the clinical trial imaging market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the clinical trial imaging market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the clinical trial imaging market across varied regions.
  • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the clinical trial imaging market.
  • Competitive Assessment: In-depth assessment of market ranking, growth strategies and service offerings of leading players like ICON plc. (Ireland), BioTelemetry Inc. (US), Biomedical Systems Corporation (US), and Medpace Holdings, Inc. (US), among others in the clinical clinical trial imaging market strategies.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 SEGMENTS CONSIDERED
    • 1.3.2 INCLUSIONS AND EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH APPROACH
    • 2.2.1 SECONDARY DATA
      • 2.2.1.1 Key data from secondary sources
      • 2.2.1.2 Objectives of secondary research
    • 2.2.2 PRIMARY DATA
      • 2.2.2.1 Objectives of primary research
      • 2.2.2.2 Key data from primary sources
      • 2.2.2.3 Key industry insights
      • 2.2.2.4 Breakdown of primaries
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 BOTTOM-UP APPROACH
      • 2.3.1.1 Company revenue estimation approach
      • 2.3.1.2 Company presentations and primary interviews
      • 2.3.1.3 Growth forecasts
      • 2.3.1.4 CAGR projections
    • 2.3.2 TOP-DOWN APPROACH
  • 2.4 DATA TRIANGULATION
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
  • 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 CLINICAL TRIAL IMAGING MARKET OVERVIEW
  • 4.2 CLINICAL TRIAL IMAGING MARKET SHARE, BY SERVICE & SOFTWARE, 2024 VS. 2029
  • 4.3 CLINICAL TRIAL IMAGING MARKET SHARE, BY MODALITY, 2024 VS. 2029
  • 4.4 CLINICAL TRIAL IMAGING MARKET SHARE, BY THERAPEUTIC AREA, 2024 VS. 2029
  • 4.5 CLINICAL TRIAL IMAGING MARKET SHARE, BY END USER, 2024 VS. 2029
  • 4.6 CLINICAL TRIAL IMAGING MARKET: REGIONAL GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing R&D spending in pharmaceutical and biotechnology companies
      • 5.2.1.2 Rising number of clinical trials in medical research
      • 5.2.1.3 Growth in pharmaceutical and biotechnology industries
      • 5.2.1.4 Increasing number of contract research organizations
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High implementation cost of imaging systems
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growth opportunities in emerging economies
      • 5.2.3.2 Development of innovative imaging modalities, contrast agents, molecular probes, and radiopharmaceuticals
    • 5.2.4 CHALLENGES
      • 5.2.4.1 High cost of clinical trials
  • 5.3 PRICING ANALYSIS
    • 5.3.1 INDICATIVE PRICING ANALYSIS FOR CLINICAL TRIAL IMAGING SERVICES & SOFTWARE, 2021-2023
  • 5.4 PATENT ANALYSIS
    • 5.4.1 LIST OF MAJOR PATENTS, 2022-2023
  • 5.5 TRADE ANALYSIS
    • 5.5.1 TRADE ANALYSIS FOR X-RAY APPARATUS (HS CODE 9022)
      • 5.5.1.1 Import data for X-ray apparatus
      • 5.5.1.2 Export data for X-ray apparatus
    • 5.5.2 TRADE ANALYSIS FOR CT APPARATUS (HS CODE 902212)
      • 5.5.2.1 Import data for CT apparatus
      • 5.5.2.2 Export data for CT apparatus
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 SUPPLY CHAIN ANALYSIS
  • 5.8 ECOSYSTEM ANALYSIS
    • 5.8.1 ROLE IN ECOSYSTEM
  • 5.9 PORTER'S FIVE FORCES ANALYSIS
    • 5.9.1 THREAT OF NEW ENTRANTS
    • 5.9.2 THREAT OF SUBSTITUTES
    • 5.9.3 BARGAINING POWER OF BUYERS
    • 5.9.4 BARGAINING POWER OF SUPPLIERS
    • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.10.2 KEY BUYING CRITERIA
  • 5.11 REGULATORY ANALYSIS
    • 5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.12 KEY CONFERENCES AND EVENTS IN 2023-2024
  • 5.13 TECHNOLOGY ANALYSIS
    • 5.13.1 KEY TECHNOLOGIES
      • 5.13.1.1 CT and MRI
    • 5.13.2 COMPLEMENTARY TECHNOLOGIES
      • 5.13.2.1 Ultrasound
  • 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.15 CASE STUDY ANALYSIS
    • 5.15.1 REVIEW OF CT FINDINGS AND HISTOPATHOLOGICAL CHARACTERISTICS OF PRIMARY LIVER CARCINOSARCOMA
  • 5.16 IMPACT OF AI/GENERATIVE AI ON CLINICAL TRIAL IMAGING MARKET

6 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE

  • 6.1 INTRODUCTION
  • 6.2 SERVICES
    • 6.2.1 OPERATIONAL IMAGING SERVICES
      • 6.2.1.1 Rising number of CROs and growing pharmaceutical industry to drive market
    • 6.2.2 READ ANALYSIS SERVICES
      • 6.2.2.1 Increasing number of clinical trials and rising R&D spending to support market growth
    • 6.2.3 SYSTEM AND TECHNICAL SUPPORT SERVICES
      • 6.2.3.1 Need for continuous technical support to propel segment growth
    • 6.2.4 TRIAL DESIGN AND CONSULTING SERVICES
      • 6.2.4.1 High R&D spending and favorable government initiatives for clinical trials to fuel market growth
  • 6.3 SOFTWARE
    • 6.3.1 NEED FOR HIGHLY EFFICIENT AND COST-EFFECTIVE CLINICAL OPERATIONS SOFTWARE TO FAVOR MARKET GROWTH

7 CLINICAL TRIAL IMAGING MARKET, BY MODALITY

  • 7.1 INTRODUCTION
  • 7.2 COMPUTED TOMOGRAPHY
    • 7.2.1 HIGHER CONTRAST IMAGE AND QUICKER TEST RESULTS TO AUGMENT SEGMENT GROWTH
  • 7.3 MAGNETIC RESONANCE IMAGING
    • 7.3.1 GREATER OBJECTIVITY, SENSITIVITY, AND REPRODUCIBILITY TO PROPEL MARKET GROWTH
  • 7.4 ULTRASOUND
    • 7.4.1 COST-EFFECTIVENESS AND EASE OF USE TO FUEL MARKET GROWTH
  • 7.5 POSITRON EMISSION TOMOGRAPHY
    • 7.5.1 ABILITY TO ASSESS PHARMACOKINETIC AND PHARMACODYNAMIC EVENTS IN HUMANS AND ANIMALS TO BOOST MARKET GROWTH
  • 7.6 X-RAY
    • 7.6.1 LOW SCANNING COST AND TECHNOLOGICAL ADVANCEMENTS TO FAVOR MARKET GROWTH
  • 7.7 OTHER MODALITIES

8 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA

  • 8.1 INTRODUCTION
  • 8.2 ONCOLOGY
    • 8.2.1 GROWING INCIDENCE OF CANCER AND INCREASING R&D INVESTMENTS BY PHARMA COMPANIES TO AID MARKET GROWTH
  • 8.3 INFECTIOUS DISEASES
    • 8.3.1 RISING DRUG DISCOVERY ACTIVITY AND GROWING DEMAND FOR THERAPEUTICS TO SPUR MARKET GROWTH
  • 8.4 NEUROLOGY
    • 8.4.1 HIGH RESEARCH INVESTMENTS FOR NEUROLOGIC DRUGS TO PROPEL MARKET GROWTH
  • 8.5 CARDIOVASCULAR SYSTEM DISORDERS
    • 8.5.1 HIGH MORTALITY RATE AND COMPLEX CLINICAL TRIAL PROCEDURES TO AUGMENT MARKET GROWTH
  • 8.6 ENDOCRINOLOGY
    • 8.6.1 RISING PREVALENCE OF DIABETES AND INCREASING RESEARCH FUNDING FOR METABOLIC DISORDERS TO DRIVE MARKET
  • 8.7 IMMUNOLOGICAL DISORDERS
    • 8.7.1 WIDE PREVALENCE OF ALLERGIES, ASTHMA, AND AUTOIMMUNE DISEASES TO SUPPORT MARKET GROWTH
  • 8.8 OTHER THERAPEUTIC AREAS

9 CLINICAL TRIAL IMAGING MARKET, BY END USER

  • 9.1 INTRODUCTION
  • 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 9.2.1 HIGH R&D BUDGETS AND FAVORABLE GOVERNMENT INITIATIVES TO SUPPORT MARKET GROWTH
  • 9.3 MEDICAL DEVICE MANUFACTURERS
    • 9.3.1 HIGH SPENDING ON R&D AND CLINICAL TRIALS TO SUPPORT MARKET GROWTH
  • 9.4 CONTRACT RESEARCH ORGANIZATIONS
    • 9.4.1 INCREASING TREND OF OUTSOURCING AND GROWING PATIENT POPULATION IN EMERGING ECONOMIES TO AID MARKET GROWTH
  • 9.5 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES
    • 9.5.1 RISING RESEARCH FUNDING AND INCREASING GOVERNMENT SUPPORT FOR CLINICAL TRIALS TO BOOST MARKET GROWTH
  • 9.6 OTHER END USERS

10 CLINICAL TRIAL IMAGING MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 10.2.2 US
      • 10.2.2.1 US to dominate North American clinical trial imaging market during study period
    • 10.2.3 CANADA
      • 10.2.3.1 Increase in per capita healthcare spending to augment market growth
  • 10.3 EUROPE
    • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 10.3.2 GERMANY
      • 10.3.2.1 Strong medical technology infrastructure and increased funding for biomedical research to augment market growth
    • 10.3.3 UK
      • 10.3.3.1 Increased R&D investments and high per capita healthcare expenditure to augment market growth
    • 10.3.4 FRANCE
      • 10.3.4.1 Developed generics market and favorable government healthcare policies to support market growth
    • 10.3.5 ITALY
      • 10.3.5.1 Increasing number of drug approvals and rising investments in clinical trials to drive market
    • 10.3.6 SPAIN
      • 10.3.6.1 Increased biologics production and improved healthcare infrastructure to aid market growth
    • 10.3.7 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 10.4.2 CHINA
      • 10.4.2.1 Favorable government regulations and presence of large target patient population to boost market growth
    • 10.4.3 JAPAN
      • 10.4.3.1 Increasing geriatric population and rising healthcare expenditure to favor market growth
    • 10.4.4 INDIA
      • 10.4.4.1 Increased government focus on developing advanced healthcare infrastructure to augment market growth
    • 10.4.5 REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 10.5.2 BRAZIL
      • 10.5.2.1 Increasing investments in biopharmaceutical research to propel market growth
    • 10.5.3 MEXICO
      • 10.5.3.1 Developed pharmaceutical and biotechnology industry and high demand for personalized medicines to aid market growth
    • 10.5.4 REST OF LATIN AMERICA
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 INCREASED FUNDING AND COLLABORATIONS IN RESEARCH SECTOR TO DRIVE MARKET
    • 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 10.7 GCC COUNTRIES
    • 10.7.1 INCREASING RESEARCH ACTIVITIES AND GROWING BIOTECHNOLOGY INDUSTRY TO SPUR MARKET GROWTH
    • 10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
    • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CLINICAL TRIAL IMAGING MARKET
  • 11.3 REVENUE ANALYSIS, 2021-2023
  • 11.4 MARKET SHARE ANALYSIS, 2023
  • 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (2023)
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 11.5.5.1 Company footprint
      • 11.5.5.2 Service & software footprint
      • 11.5.5.3 Therapeutic area footprint
      • 11.5.5.4 Region footprint
  • 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 RESPONSIVE COMPANIES
    • 11.6.3 DYNAMIC COMPANIES
    • 11.6.4 STARTING BLOCKS
    • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 11.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 11.8 COMPETITIVE SCENARIO
    • 11.8.1 SERVICE AND SOLUTION LAUNCHES AND REGULATORY APPROVALS
    • 11.8.2 DEALS

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
    • 12.1.1 ICON PLC
      • 12.1.1.1 Business overview
      • 12.1.1.2 Services/Solutions offered
      • 12.1.1.3 Recent developments
        • 12.1.1.3.1 Solution launches
        • 12.1.1.3.2 Deals
      • 12.1.1.4 MnM view
        • 12.1.1.4.1 Key strengths
        • 12.1.1.4.2 Strategic choices
        • 12.1.1.4.3 Weaknesses and competitive threats
    • 12.1.2 MEDPACE
      • 12.1.2.1 Business overview
      • 12.1.2.2 Services/Solutions offered
      • 12.1.2.3 MnM view
        • 12.1.2.3.1 Key strengths
        • 12.1.2.3.2 Strategic choices
        • 12.1.2.3.3 Weaknesses and competitive threats
    • 12.1.3 CLARIO
      • 12.1.3.1 Business overview
      • 12.1.3.2 Services/Solutions offered
      • 12.1.3.3 Recent developments
        • 12.1.3.3.1 Solution launches
        • 12.1.3.3.2 Deals
      • 12.1.3.4 MnM view
        • 12.1.3.4.1 Key strengths
        • 12.1.3.4.2 Strategic choices
        • 12.1.3.4.3 Weaknesses and competitive threats
    • 12.1.4 IXICO PLC
      • 12.1.4.1 Business overview
      • 12.1.4.2 Services/Solutions offered
      • 12.1.4.3 Recent developments
        • 12.1.4.3.1 Deals
        • 12.1.4.3.2 Other developments
    • 12.1.5 RESONANCE HEALTH LTD.
      • 12.1.5.1 Business overview
      • 12.1.5.2 Services/Solutions offered
      • 12.1.5.3 Recent developments
        • 12.1.5.3.1 Service launches and regulatory approvals
        • 12.1.5.3.2 Deals
    • 12.1.6 RADIANT SAGE
      • 12.1.6.1 Business overview
      • 12.1.6.2 Services/Solutions offered
    • 12.1.7 WCG CLINICAL
      • 12.1.7.1 Business overview
      • 12.1.7.2 Services/Solutions offered
      • 12.1.7.3 Recent developments
        • 12.1.7.3.1 Deals
    • 12.1.8 CARDIOVASCULAR IMAGING TECHNOLOGIES
      • 12.1.8.1 Business overview
      • 12.1.8.2 Services/Solutions offered
  • 12.2 OTHER PLAYERS
    • 12.2.1 MEDICAL METRICS, INC.
    • 12.2.2 PRISM CLINICAL IMAGING
    • 12.2.3 BOSTON IMAGING CORE LAB
    • 12.2.4 ANAGRAM 4 CLINICAL TRIALS
    • 12.2.5 VOIANT
    • 12.2.6 CALYX
    • 12.2.7 BIOSPECTIVE INC.
    • 12.2.8 PROSCAN IMAGING
    • 12.2.9 MICRON, INC.
    • 12.2.10 IMAGING ENDPOINTS
    • 12.2.11 PERSPECTUM
    • 12.2.12 PHARMTRACE
    • 12.2.13 NAVITAS LIFE SCIENCES
    • 12.2.14 MEDIAN TECHNOLOGIES
    • 12.2.15 INVICRO, LLC
    • 12.2.16 IMAGE CORE LAB
    • 12.2.17 IMAGE ANALYSIS GROUP (IAG)

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 CLINICAL TRIAL IMAGING MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 CLINICAL TRIAL IMAGING MARKET: KEY DATA FROM PRIMARY SOURCES
  • TABLE 3 CLINICAL TRIAL IMAGING MARKET: RISK ASSESSMENT ANALYSIS
  • TABLE 4 INDICATIVE SELLING PRICE TREND FOR CLINICAL TRIAL IMAGING SERVICES & SOFTWARE, 2021-2023
  • TABLE 5 CLINICAL TRIAL IMAGING MARKET: LIST OF KEY PATENTS, JANUARY 2022-DECEMBER 2023
  • TABLE 6 IMPORT DATA FOR X-RAY APPARATUS (HS CODE 9022), BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 7 EXPORT DATA FOR X-RAY APPARATUS (HS CODE 9022), BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 8 IMPORT DATA FOR CT APPARATUS (HS CODE 902212), BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 9 EXPORT DATA FOR CT APPARATUS (HS CODE 902212), BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 10 CLINICAL TRIAL IMAGING MARKET: ROLE IN ECOSYSTEM
  • TABLE 11 CLINICAL TRIAL IMAGING MARKET: IMPACT OF PORTER'S FIVE FORCES
  • TABLE 12 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
  • TABLE 13 KEY BUYING CRITERIA FOR MAJOR END USERS
  • TABLE 14 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 CLINICAL TRIAL IMAGING MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, JANUARY 2023-DECEMBER 2024
  • TABLE 20 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022-2029 (USD MILLION)
  • TABLE 21 CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 22 CLINICAL TRIAL IMAGING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 23 NORTH AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 24 EUROPE: CLINICAL TRIAL IMAGING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 25 ASIA PACIFIC: CLINICAL TRIAL IMAGING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 26 LATIN AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 27 OPERATIONAL IMAGING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 28 NORTH AMERICA: OPERATIONAL IMAGING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 29 EUROPE: OPERATIONAL IMAGING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 30 ASIA PACIFIC: OPERATIONAL IMAGING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 31 LATIN AMERICA: OPERATIONAL IMAGING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 32 READ ANALYSIS SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 33 NORTH AMERICA: READ ANALYSIS SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 34 EUROPE: READ ANALYSIS SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 35 ASIA PACIFIC: READ ANALYSIS SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 36 LATIN AMERICA: READ ANALYSIS SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 37 SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 38 NORTH AMERICA: SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 39 EUROPE: SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 40 ASIA PACIFIC: SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 41 LATIN AMERICA: SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 42 TRIAL DESIGN AND CONSULTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 43 NORTH AMERICA: TRIAL DESIGN AND CONSULTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 44 EUROPE: TRIAL DESIGN AND CONSULTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 45 ASIA PACIFIC: TRIAL DESIGN AND CONSULTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 46 LATIN AMERICA: TRIAL DESIGN AND CONSULTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 47 CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 48 NORTH AMERICA: CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 49 EUROPE: CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 50 ASIA PACIFIC: CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 51 LATIN AMERICA: CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 52 CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 53 CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 54 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 55 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 56 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 57 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 58 CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 59 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 60 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 61 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 62 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 63 CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 64 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 65 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 66 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 67 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 68 CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 69 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 70 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 71 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 72 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 73 CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 74 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 75 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 76 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 77 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 78 CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 79 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 80 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 81 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 82 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 83 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 84 CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 85 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 86 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 87 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 88 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 89 CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 90 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 91 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 92 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 93 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 94 CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 95 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 96 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 97 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 98 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 99 CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 100 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 101 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 102 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 103 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 104 CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 105 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 106 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 107 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 108 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 109 CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 110 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 111 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 112 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 113 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 114 CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 115 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 116 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 117 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 118 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 119 CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 120 CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 121 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 122 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 123 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 124 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 125 CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 126 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 127 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 128 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 129 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 130 CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 131 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 132 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 133 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 134 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 135 CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 136 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 137 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 138 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 139 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 140 CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 141 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 142 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 143 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 144 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 145 CLINICAL TRIAL IMAGING MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 146 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 147 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022-2029 (USD MILLION)
  • TABLE 148 NORTH AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 149 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 150 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 151 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 152 NORTH AMERICA: KEY MACROINDICATORS
  • TABLE 153 US: LIST OF PRODUCT APPROVALS BY KEY PLAYERS, 2020-2023
  • TABLE 154 US: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022-2029 (USD MILLION)
  • TABLE 155 US: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 156 US: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 157 US: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 158 US: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 159 CANADA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022-2029 (USD MILLION)
  • TABLE 160 CANADA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 161 CANADA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 162 CANADA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 163 CANADA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 164 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 165 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022-2029 (USD MILLION)
  • TABLE 166 EUROPE: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 167 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 168 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 169 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 170 EUROPE: KEY MACROINDICATORS
  • TABLE 171 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022-2029 (USD MILLION)
  • TABLE 172 GERMANY: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 173 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 174 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 175 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 176 UK: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022-2029 (USD MILLION)
  • TABLE 177 UK: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 178 UK: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 179 UK: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 180 UK: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 181 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022-2029 (USD MILLION)
  • TABLE 182 FRANCE: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 183 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 184 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 185 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 186 ITALY: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022-2029 (USD MILLION)
  • TABLE 187 ITALY: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 188 ITALY: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 189 ITALY: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 190 ITALY: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 191 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022-2029 (USD MILLION)
  • TABLE 192 SPAIN: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 193 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 194 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 195 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 196 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022-2029(USD MILLION)
  • TABLE 197 REST OF EUROPE: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 198 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 199 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 200 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 201 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 202 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022-2029 (USD MILLION)
  • TABLE 203 ASIA PACIFIC: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 204 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 205 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 206 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 207 ASIA PACIFIC: KEY MACROINDICATORS
  • TABLE 208 CHINA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022-2029 (USD MILLION)
  • TABLE 209 CHINA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 210 CHINA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 211 CHINA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 212 CHINA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 213 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022-2029 (USD MILLION)
  • TABLE 214 JAPAN: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 215 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 216 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 217 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 218 INDIA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022-2029 (USD MILLION)
  • TABLE 219 INDIA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 220 INDIA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 221 INDIA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 222 INDIA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 223 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022-2029 (USD MILLION)
  • TABLE 224 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 225 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 226 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 227 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 228 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 229 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022-2029 (USD MILLION)
  • TABLE 230 LATIN AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 231 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 232 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 233 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 234 LATIN AMERICA: KEY MACROINDICATORS
  • TABLE 235 BRAZIL: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022-2029 (USD MILLION)
  • TABLE 236 BRAZIL: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 237 BRAZIL: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 238 BRAZIL: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 239 BRAZIL: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 240 MEXICO: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022-2029 (USD MILLION)
  • TABLE 241 MEXICO: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 242 MEXICO: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 243 MEXICO: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 244 MEXICO: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 245 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022-2029 (USD MILLION)
  • TABLE 246 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 247 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 248 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 249 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 250 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022-2029 (USD MILLION)
  • TABLE 251 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 252 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 253 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 254 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 255 MIDDLE EAST & AFRICA: KEY MACROINDICATORS
  • TABLE 256 GCC COUNTRIES: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022-2029 (USD MILLION)
  • TABLE 257 GCC COUNTRIES: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 258 GCC COUNTRIES: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 259 GCC COUNTRIES: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 260 GCC COUNTRIES: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 261 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN CLINICAL TRIAL IMAGING MARKET
  • TABLE 262 CLINICAL TRIAL IMAGING MARKET: DEGREE OF COMPETITION
  • TABLE 263 CLINICAL TRIAL IMAGING MARKET: SERVICE & SOFTWARE FOOTPRINT
  • TABLE 264 CLINICAL TRIAL IMAGING MARKET: THERAPEUTIC AREA FOOTPRINT
  • TABLE 265 CLINICAL TRIAL IMAGING MARKET: REGION FOOTPRINT
  • TABLE 266 CLINICAL TRIAL IMAGING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 267 CLINICAL TRIAL IMAGING MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUP/SME PLAYERS
  • TABLE 268 CLINICAL TRIAL IMAGING MARKET: SERVICE AND SOLUTION LAUNCHES AND REGULATORY APPROVALS, JANUARY 2020-AUGUST 2024
  • TABLE 269 CLINICAL TRIAL IMAGING MARKET: DEALS, JANUARY 2020-AUGUST 2024
  • TABLE 270 ICON PLC: COMPANY OVERVIEW
  • TABLE 271 ICON PLC: SERVICES/SOLUTIONS OFFERED
  • TABLE 272 ICON PLC: SOLUTION LAUNCHES, JANUARY 2020-AUGUST 2024
  • TABLE 273 ICON PLC: DEALS, JANUARY 2020-AUGUST 2024
  • TABLE 274 MEDPACE: COMPANY OVERVIEW
  • TABLE 275 MEDPACE: SERVICES/SOLUTIONS OFFERED
  • TABLE 276 CLARIO: COMPANY OVERVIEW
  • TABLE 277 CLARIO: SERVICES/SOLUTIONS OFFERED
  • TABLE 278 CLARIO: SOLUTION LAUNCHES, JANUARY 2020-AUGUST 2024
  • TABLE 279 CLARIO: DEALS, JANUARY 2020-AUGUST 2024
  • TABLE 280 IXICO PLC: COMPANY OVERVIEW
  • TABLE 281 IXICO PLC: SERVICES/SOLUTIONS OFFERED
  • TABLE 282 IXICO PLC: DEALS, JANUARY 2020-AUGUST 2024
  • TABLE 283 IXICO PLC: OTHER DEVELOPMENTS, JANUARY 2020-AUGUST 2024
  • TABLE 284 RESONANCE HEALTH LTD.: COMPANY OVERVIEW
  • TABLE 285 RESONANCE HEALTH LTD.: SERVICES/SOLUTIONS OFFERED
  • TABLE 286 RESONANCE HEALTH LTD.: SERVICE LAUNCHES AND REGULATORY APPROVALS, JANUARY 2020-AUGUST 2024
  • TABLE 287 RESONANCE HEALTH LTD.: DEALS, JANUARY 2020-AUGUST 2024
  • TABLE 288 RADIANT SAGE: COMPANY OVERVIEW
  • TABLE 289 RADIANT SAGE: SERVICES/SOLUTIONS OFFERED
  • TABLE 290 WCG CLINICAL: COMPANY OVERVIEW
  • TABLE 291 WCG CLINICAL: SERVICES/SOLUTIONS OFFERED
  • TABLE 292 WCG CLINICAL: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 293 CARDIOVASCULAR IMAGING TECHNOLOGIES: COMPANY OVERVIEW
  • TABLE 294 CARDIOVASCULAR IMAGING TECHNOLOGIES: SERVICES/SOLUTIONS OFFERED
  • TABLE 295 MEDICAL METRICS, INC.: COMPANY OVERVIEW
  • TABLE 296 PRISM CLINICAL IMAGING: COMPANY OVERVIEW
  • TABLE 297 BOSTON IMAGING CORE LAB: COMPANY OVERVIEW
  • TABLE 298 ANAGRAM 4 CLINICAL TRIALS: COMPANY OVERVIEW
  • TABLE 299 VOIANT: COMPANY OVERVIEW
  • TABLE 300 CALYX: COMPANY OVERVIEW
  • TABLE 301 BIOSPECTIVE INC.: COMPANY OVERVIEW
  • TABLE 302 PROSCAN IMAGING: COMPANY OVERVIEW
  • TABLE 303 MICRON, INC.: COMPANY OVERVIEW
  • TABLE 304 IMAGING ENDPOINTS: COMPANY OVERVIEW
  • TABLE 305 PERSPECTUM: COMPANY OVERVIEW
  • TABLE 306 PHARMTRACE: COMPANY OVERVIEW
  • TABLE 307 NAVITAS LIFE SCIENCES: COMPANY OVERVIEW
  • TABLE 308 MEDIAN TECHNOLOGIES: COMPANY OVERVIEW
  • TABLE 309 INVICRO, LLC: COMPANY OVERVIEW
  • TABLE 310 IMAGE CORE LAB: COMPANY OVERVIEW
  • TABLE 311 IMAGE ANALYSIS GROUP (IAG): COMPANY OVERVIEW

List of Figures

  • FIGURE 1 CLINICAL TRIAL IMAGING MARKET: SEGMENTS CONSIDERED
  • FIGURE 2 CLINICAL TRIAL IMAGING MARKET: YEARS CONSIDERED
  • FIGURE 3 CLINICAL TRIAL IMAGING MARKET: RESEARCH DESIGN
  • FIGURE 4 CLINICAL TRIAL IMAGING MARKET: KEY DATA FROM SECONDARY SOURCES
  • FIGURE 5 CLINICAL TRIAL IMAGING MARKET: KEY PRIMARY SOURCES (DEMAND AND SUPPLY SIDES)
  • FIGURE 6 CLINICAL TRIAL IMAGING MARKET: KEY INSIGHTS FROM PRIMARIES
  • FIGURE 7 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 9 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
  • FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 11 CLINICAL TRIAL IMAGING MARKET: TOP-DOWN APPROACH
  • FIGURE 12 DATA TRIANGULATION METHODOLOGY
  • FIGURE 13 CLINICAL TRIAL IMAGING MARKET: STUDY ASSUMPTIONS
  • FIGURE 14 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2024 VS. 2029 (USD MILLION)
  • FIGURE 16 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2024 VS. 2029 (USD MILLION)
  • FIGURE 17 CLINICAL TRIAL IMAGING MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 18 CLINICAL TRIAL IMAGING MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 19 INCREASE IN R&D SPENDING TO DRIVE MARKET GROWTH
  • FIGURE 20 SERVICES TO DOMINATE CLINICAL TRIAL IMAGING SERVICE & SOFTWARE MARKET IN 2029
  • FIGURE 21 COMPUTED TOMOGRAPHY TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
  • FIGURE 22 ONCOLOGY TO COMMAND LARGEST MARKET SHARE IN 2029
  • FIGURE 23 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE END-USER MARKET FROM 2024 TO 2029
  • FIGURE 24 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING STUDY PERIOD
  • FIGURE 25 CLINICAL TRIAL IMAGING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 26 NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000-2022)
  • FIGURE 27 PATENT APPLICATIONS FOR CLINICAL TRIAL IMAGING (JANUARY 2013-DECEMBER 2023)
  • FIGURE 28 CLINICAL TRIAL IMAGING MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 29 CLINICAL TRIAL IMAGING MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 30 CLINICAL TRIAL IMAGING MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 31 CLINICAL TRIAL IMAGING MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 32 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF CLINICAL TRIAL IMAGING SERVICES/SOLUTIONS
  • FIGURE 33 KEY BUYING CRITERIA FOR MAJOR END USERS
  • FIGURE 34 CLINICAL TRIAL IMAGING MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 35 R&D INVESTMENTS IN PHARMACEUTICAL INDUSTRY, 2012-2026 (USD BILLION)
  • FIGURE 36 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET SNAPSHOT
  • FIGURE 37 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET SNAPSHOT
  • FIGURE 38 REVENUE ANALYSIS OF KEY PLAYERS IN CLINICAL TRIAL IMAGING MARKET (2021-2023)
  • FIGURE 39 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CLINICAL TRIAL IMAGING MARKET (2023)
  • FIGURE 40 CLINICAL TRIAL IMAGING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 41 CLINICAL TRIAL IMAGING MARKET: COMPANY FOOTPRINT
  • FIGURE 42 CLINICAL TRIAL IMAGING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 43 EV/EBITDA OF KEY VENDORS
  • FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 45 ICON PLC: COMPANY SNAPSHOT
  • FIGURE 46 MEDPACE: COMPANY SNAPSHOT
  • FIGURE 47 IXICO PLC: COMPANY SNAPSHOT
  • FIGURE 48 RESONANCE HEALTH LTD.: COMPANY SNAPSHOT